Avenge Bio Announces Successful Completion of First Dose Level Cohort in Phase 1/2 Clinical Trial of AVB-001 for the Treatment of Ovarian Cancer by Carolyn Helms | Apr 26, 2023 | Portfolio News
Cortica Closes $75 Million in New Funding Round and Acquires Springtide Child Development by Carolyn Helms | Apr 18, 2023 | Portfolio News
IntelyCare Introduces Technology Partnership with UKG to Alleviate Nursing Workforce Challenges by Carolyn Helms | Apr 13, 2023 | Portfolio News
Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect by Carolyn Helms | Apr 12, 2023 | Portfolio News
Landmark New England Journal of Medicine Publication Reports Positive Results From PROMISE II Pivotal Trial Showing that LimFlow System Saves Most Patients with End-stage Peripheral Artery Disease From Major Amputation by Carolyn Helms | Mar 30, 2023 | Portfolio News
